Phase IMitochondrial Peptide
Compound 61620
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061620
Risk Class
LOW
Last Audit
May 10, 2108
Research Abstract
Mitochondrial Peptide candidate engineered for metabolic regulation initiatives with automated dossier coverage.
Compound 61620 is a mitochondrial peptide asset inside mitochondrial peptide innovation track initiatives, optimized for metabolic regulation and cardiometabolic recovery.
The dossier currently sits in phase i with a low risk rating, meaning it is cleared for baseline monitoring protocols.
Supply records cite CAS AUTO-061620 with updates logged 2108-05-10.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Metabolic regulationCardiometabolic recovery
Nomenclature
CX-61620Mitochondrial Peptide Program 61620
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061620
- [2] Operations Pulse • Mitochondrial Peptide innovation track
- [3] Risk Governance Ledger • LOW clearance for COMPOUND-61620